var data={"title":"Topotecan: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Topotecan: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7075?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=topotecan-drug-information\" class=\"drug drug_general\">see &quot;Topotecan: Drug information&quot;</a> and <a href=\"topic.htm?path=topotecan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Topotecan: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708912\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan can cause severe myelosuppression. Administer only to patients with baseline neutrophil counts of &ge;1,500 cells/mm<sup>3</sup> and a platelet count of &ge;100,000 cells/mm<sup>3</sup>. Monitor blood cell counts.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229294\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hycamtin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229295\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Hycamtin;</li>\n      <li>Topotecan For Injection;</li>\n      <li>Topotecan Hydrochloride For Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050402\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Camptothecin</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Topoisomerase Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050394\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=topotecan-drug-information\" class=\"drug drug_general\">see &quot;Topotecan: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In adults, baseline neutrophil count should be &ge;1500/mm<sup>3</sup> and platelets should be &ge;100,000/mm<sup>3</sup> prior to treatment; for retreatment, neutrophil count should be &gt;1000/mm<sup>3</sup>; platelets &gt;100,000/mm<sup>3</sup> and hemoglobin &ge;9 g/dL; consult individual pediatric protocols for details regarding baseline neutrophil and platelet counts and hemoglobin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol. In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphoblastic leukemia; recurrent (first relapse):</b> Children and Adolescents: Induction therapy: IV: 2.4 mg/m<sup>2</sup>/dose once daily for 7 to 9 days (Furman 2002; Hijiya 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia; recurrent, refractory:</b> Children and Adolescents: IV: Initial: 4 mg/m<sup>2</sup>/dose once on day 1; subsequent daily doses (days 2 to 5) determined by pharmacokinetic analysis (target AUC: 140 &plusmn; 20 ng/mL/hour) and administered once daily (in combination with cladribine); the median reported topotecan dose was 4 mg/m<sup>2</sup>/day (range: 1.7 to 6 mg/m<sup>2</sup>/day) (Inaba 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS malignancies, including gliomas:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing: Infants, Children, and Adolescents: Oral (using reconstituted lyophilized parenteral formulation): 0.8 mg/m<sup>2</sup>/dose once daily for 21 days of a 28-day cycle was used in 25 pediatric patients (median age: 9.2 years; range 0.8 to 23 years) with recurrent brain tumors, including gliomas, medulloblastoma, and ependymoma; the reported median number of cycles: 1.9 [range: 0.5 to 15 cycles (months)] (Minturn 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose escalation: Children &ge;3 years and Adolescents: Oral (using reconstituted lyophilized parenteral formulation): Initial: 0.4 mg/m<sup>2</sup>/dose once daily was used in a trial of 32 pediatric patients (median age: 9.5 years, range: 3 to 18 years) with recurrent or progression of high-grade glioma; dosage was increased based upon patient tolerance and individual dose-limiting toxicity; doses were increased in 0.2 mg/m<sup>2</sup> increments at weekly intervals for the first 2 weeks of therapy and then increased in 0.1 mg/m<sup>2</sup> increments at weekly intervals up to the maximum dose of 2 mg/m<sup>2</sup>/day; once the patient's maximum tolerated dose was reached, the daily dose was decreased until toxicity became acceptable; reported final median maximum tolerated dose: 0.9 mg/m<sup>2</sup>/day (range: 0.6 to 2 mg/m<sup>2</sup>/day); median duration of therapy: 3 months (range: 21 days to 1 year) (Wagner 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuroblastoma:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction:</i> Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &le;12 kg: 0.04 mg/<b>kg</b>/dose once daily for 5 days (in combination with cyclophosphamide); repeat cycle every 21 days for 6 cycles (Park 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &gt;12 kg: Initial: 1.2 mg/m<sup>2</sup>/dose once daily for 5 days (in combination with cyclophosphamide); repeat cycle every 21 days for 6 cycles (Park 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Pharmacokinetic analysis was used to guide topotecan therapy during the first 2 cycles using a target AUC: 50 to 70 ng/mL/hour; median dose for cycle 1 was 1.2 mg/m<sup>2</sup>/day (range: 0.75 to 2.1 mg/m<sup>2</sup>/day) and for cycle 2, the median dose was 1.3 mg/m<sup>2</sup>/day (range: 1.2 to 2.9 mg/m<sup>2</sup>/day) (Park 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Recurrent, refractory, or untreated metastatic disease:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Combination therapy: 0.75 mg/m<sup>2</sup>/dose once daily for 5 days (in combination with cyclophosphamide); repeat cycle every 21 days (Ashraf 2013; Kretschmar 2004; London 2010; Saylors 2001; Zage 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Monotherapy: 2 mg/m<sup>2</sup>/day for 5 days (London 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral (using reconstituted lyophilized parenteral formulation): Children &ge;2 years and Adolescents: 0.8 mg/m<sup>2</sup>/dose once daily for 14 days (in combination with oral cyclophosphamide); repeat cycle every 21 to 28 days (Bowers 2004). In a Phase I dose escalation trial of 20 pediatric patients (median age: 10.6 years) with refractory solid tumors including neuroblastoma, a daily dose of 1.8 mg/m<sup>2</sup> once daily for 5 days, followed by 2 days rest, then another 5 days of therapy (one cycle: 10 doses over 12 days); repeat cycle every 28 days was shown to stabilize disease in some patients (Daw, 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematopoietic stem-cell transplant; conditioning:</b> Children and Adolescents: IV: 2 mg/m<sup>2</sup>/dose on days -8 through -4 prior to stem cell transfusion (total dose: 10 mg/m<sup>2</sup>), in combination with carboplatin and thiotepa, was used in 21 patients (median age: 4.1 years; range: 1-29 years) with refractory solid tumors (neuroblastoma: n=11) (Kushner, 2001). In a Phase I/II trial of 51 patients (median age: 5.1 years; range: 1.5 to 21 years), an initial dose of: 3 mg/m<sup>2</sup>/dose on day -11 was used with subsequent doses (days -10 through -2; 10 days total of topotecan therapy) determined by pharmacokinetic analysis (target AUC: 100 &plusmn; 20 ng/mL/hour) and administered once daily (in combination with cyclophosphamide on days -6 through -2); the median reported topotecan dose was 3.1 mg/m<sup>2</sup>/day (range: 1.1 to 4.6 mg/m<sup>2</sup>/day) (Kaskow 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pediatric solid tumors; recurrent or refractory or untreated metastatic including rhabdosarcoma, Ewing sarcoma:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Combination therapy: 0.75 mg/m<sup>2</sup>/dose once daily for 5 days every 21 days in combination with cyclophosphamide (Bernstien 2006; Hunhold 2006; Saylors 2001; Waterhouse 2004) or with cyclophosphamide and vincristine (VTC regimen) (Pappo 2001); this dosing has also been administered in combination with temozolomide in 28-day cycles (TOTEM regimen) (Rubie 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Single-agent therapy (window therapy): 2-2.4 mg/m<sup>2</sup>/dose once daily for 5 days every 21 days (Pappo 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral [using reconstituted lyophilized parenteral formulation or oral capsules (for patients able to swallow)]: Children &ge;3 years and Adolescents: 1.8 mg/m<sup>2</sup> once daily for 5 days, followed by 2 days rest, then another 5 days of therapy (one cycle: 10 doses over 12 days); repeat cycle every 28 days; when using oral capsules, doses were rounded to the nearest 0.25 mg; dosing based on a Phase I trial dose escalation trial of 20 pediatric patients (median age: 10.6 years) with refractory solid tumors (Daw 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cervical cancer, recurrent or resistant:</b> IV: 0.75 mg/m<sup>2</sup>/day for 3 days [followed by cisplatin on day 1 only (with hydration)] every 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ovarian cancer, metastatic:</b> IV: 1.5 mg/m<sup>2</sup>/day for 5 consecutive days every 21 days, minimum of 4 cycles recommended in the absence of tumor progression <b>or</b> (weekly administration) 4 mg/m<sup>2</sup> on days 1, 8, and 15 every 28 days until disease progression or unacceptable toxicity or a maximum of 12 months (Sehouli 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Small cell lung cancer, relapsed or refractory: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 1.5 mg/m<sup>2</sup>/day for 5 consecutive days every 21 days, minimum of 4 cycles recommended in the absence of tumor progression</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 2.3 mg/m<sup>2</sup>/day for 5 consecutive days every 21 days (round dose to the nearest 0.25 mg); if patient vomits after dose is administered, do not give a replacement dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Consult protocol for specific recommendations. Some centers have considered the following adjustments: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Baseline:</i> Initial dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;40 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 40 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;20 mL/minute/1.73 m<sup>2</sup>: Hold doses until renal function recovers (CrCl &gt;20 mL/minute/1.73 m<sup>2</sup>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>During therapy: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;60 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 40 to 60 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to &lt;40 mL/minute/1.73 m<sup>2</sup>: Administer 25% to 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;20 mL/minute/1.73 m<sup>2</sup>: Hold doses until renal function recovers (CrCl &gt;20 mL/minute/1.73 m<sup>2</sup>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Very limited data available; some data suggest that clearance of the lactone metabolite is similar to pediatric patients with normal renal function; a case report describes topotecan use in an anephric 6-year old diagnosed with Wilms tumor; the patient received 0.75 mg/m<sup>2</sup>/dose once daily for 5 days every 21 days with hemodialysis on day 2 and 4; on dialysis days, topotecan was administered ~2 hours before the start of the dialysis session; dosage reductions required for toxicity (myelosuppression) after cycle 4 (Aronoff 2007; Iacono 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Administer 50% of dose or reduce dose by 0.75 mg/m<sup>2</sup>/dose, if appropriate (Aronoff, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &ge;40 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 20 to 39 mL/minute: Reduce dose to 0.75 mg/m<sup>2</sup>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;20 mL/minute: There are no dosage adjustments provided in manufacturer's U.S. labeling (insufficient data available for dosing recommendation).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note</b>: For topotecan in combination with cisplatin for cervical cancer, do not initiate treatment in patients with serum creatinine &gt;1.5 mg/dL; consider discontinuing treatment in patients with serum creatinine &gt;1.5 mg/dL in subsequent cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 30 to 49 mL/minute: Reduce dose to 1.8 mg/m<sup>2</sup>/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in manufacturer's U.S. labeling (insufficient data available for dosing recommendation).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aronoff, 2007: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &gt;50 mL/minute: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 10 to 50 mL/minute: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;10 mL/minute: Administer 25% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: Avoid use</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous ambulatory peritoneal dialysis (CAPD): Avoid use</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous renal replacement therapy (CRRT): 0.75 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Kintzel, 1995: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 46 to 60 mL/minute: Administer 80% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 31 to 45 mL/minute: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &le;30 mL/minute: Administer 70% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Bilirubin 1.7 to 15 mg/dL: No adjustment necessary; the half-life is increased slightly; usual doses are generally tolerated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Bilirubin &gt;1.5 mg/dL: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Cervical cancer:</b> IV: Severe febrile neutropenia (&lt;1000/mm<sup>3</sup> with temperature of 38&deg;C) or platelet count &lt;25,000/mm<sup>3</sup>: Reduce topotecan to 0.6 mg/m<sup>2</sup>/day for subsequent cycles [may consider GCSF support (beginning on day 4) prior to instituting dose reduction for neutropenic fever]. <b>Note:</b> Cisplatin may also require dose adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For neutropenic fever despite G-SCF use, reduce dose to 0.45 mg/m<sup>2</sup>/day for subsequent cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Ovarian cancer:</b> IV: Dosage adjustment for hematological effects: Severe neutropenia (&lt;500/mm<sup>3</sup>) or platelet count &lt;25,000/mm<sup>3</sup>: Reduce dose to 1.25 mg/m<sup>2</sup>/day for subsequent cycles [may consider G-CSF support (beginning on day 6) prior to instituting dose reduction for neutropenia]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Small cell lung cancer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Dosage adjustment for hematological effects: Severe neutropenia (&lt;500/mm<sup>3</sup>) or platelet count &lt;25,000/mm<sup>3</sup>: Reduce dose to 1.25 mg/m<sup>2</sup>/day for subsequent cycles [may consider G-CSF support (beginning on day 6) prior to instituting dose reduction for severe neutropenia]</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: Severe neutropenia (neutrophils &lt;500/mm<sup>3</sup> associated with fever or infection or lasting &ge;7 days) or prolonged neutropenia (neutrophils &ge;500/mm<sup>3</sup> to &le;1000/mm<sup>3</sup> lasting beyond day 21) or platelets &lt;25,000/mm<sup>3</sup> or grades 3 or 4 diarrhea: Reduce dose by 0.4 mg/m<sup>2</sup>/day for subsequent cycles (may consider same dosage reduction for grade 2 diarrhea if clinically indicated)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229271\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hycamtin: 0.25 mg, 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/4 mL (4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hycamtin: 4 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229256\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050405\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IV: Administer by intermittent infusion over 30 minutes.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules: May administer with or without food. Swallow capsule whole; do not crush, chew, or divide capsule. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Parenteral formulation; lyophilized powder for oral use. After reconstitution, mix dose in 30 mL of an acidic medium (eg, apple, grape, or orange juice); <b>Note:</b> The reconstituted injectable solution is tasteless; the acidic medium serves as the vehicle only, not to mask the taste (Bowers 2004; Daw 2004; Minturn 2001; Wagner 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132737\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for IV preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during IV administration. NIOSH recommends single gloving for administration of an intact tablet/capsule (NIOSH 2016). If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229286\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution for injection: Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 45&deg;F). Protect from light. Single-use vials should be discarded after initial vial entry. Stability of solutions diluted for infusion is variable; refer to specific product information for details.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lyophilized powder: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Reconstituted solution is stable for up to 28 days at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F), although the manufacturer recommends use immediately after reconstitution. Solutions diluted in D<sub>5</sub>W or NS are stable for 24 hours at room temperature (manufacturer's labeling) or up to 7 days under refrigeration (Craig 1997). Reconstituted solution for injection (reconstituted with bacteriostatic SWFI to 1 mg/mL) for oral administration is stable for 14 days at 4&deg;C in plastic syringes (Daw 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050404\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of metastatic ovarian cancer; relapsed or refractory small cell lung cancer; recurrent or resistant (stage IVB) cervical cancer (in combination with cisplatin) (All indications: FDA approved in adults); has also been used in pediatric solid tumors including Ewing&rsquo;s sarcoma, osteosarcoma, rhabdomyosarcoma, and neuroblastoma and acute leukemias (ALL, AML) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229339\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hycamtin may be confused with Mycamine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topotecan may be confused with irinotecan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Topotecan overdoses have been reported; potential causes include omission of the leading zero and missing the decimal point when prescribing, preparing, and administering. Recommended intravenous doses should generally not exceed 4 mg; verify dose prior to administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229336\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Fatigue (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Alopecia (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea (oral), anorexia (more common with intravenous), diarrhea (more common with oral), vomiting (oral), abdominal pain (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (more common with oral), neutropenia (more common with oral; nadir 12 to 15 days; duration: 7 days), thrombocytopenia (more common with oral; nadir: 15 days; duration: 3 to 5 days), febrile neutropenia (more common with intravenous), neutropenic infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased liver enzymes (intravenous; transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever (oral), sepsis (more common with intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Dermatitis (severe), extravasation, hemorrhage (severe, associated with thrombocytopenia), hypersensitivity reaction, interstitial pulmonary disease, leukopenia, myalgia, neutropenic enterocolitis, pancytopenia, paresthesia, pruritus (severe), skin rash, stomatitis, typhlitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229277\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hypersensitivity to topotecan or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe renal impairment (CrCl &lt;20 mL/minute); pregnancy; breastfeeding; severe bone marrow depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229260\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: May cause severe myelosuppression. Monitor blood counts frequently. Do NOT administer to patients with baseline neutrophils &lt;1,500/mm<sup>3</sup> and platelets &lt;100,000/mm<sup>3</sup>.</b> The dose-limiting toxicity is bone marrow suppression (primarily neutropenia); may also cause thrombocytopenia and anemia. Grade 3 and 4 events were common. Severe myelotoxicity has also been reported when used in combination with cisplatin. Neutropenia is not cumulative over time. The median duration of neutropenia and thrombocytopenia was 7 days and 5 days, respectively. Nadir neutrophil and platelet counts occurred at a median of 15 days (when administered orally). In a clinical study comparing IV to oral topotecan, G-CSF support was administered in a higher percentage of patients receiving oral topotecan (Eckardt 2007). Bone marrow suppression may require dosage reduction and/or growth factor support.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Extravasation injuries have been reported (some severe); if extravasation occurs, discontinue infusion immediately and manage appropriately. Ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Diarrhea has been reported with oral topotecan; may be severe (requiring hospitalization); educate patients on early recognition and proper management, including diet changes, increase in fluid intake, antidiarrheals, and antibiotics. The median time to onset of diarrhea (grade 2 or worse) was 9 days. The incidence of diarrhea may be higher in the elderly. Do not administer in patients with grade 3 or 4 diarrhea; reduce dose upon recovery to &le; grade 1 toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interstitial lung disease (ILD): ILD (with fatalities) has been reported; monitor for pulmonary signs/symptoms (eg, dyspnea, fever, cough, hypoxia) and discontinue use in patients with confirmed ILD diagnosis. Risk factors for ILD include a history of ILD, pulmonary fibrosis, lung cancer, thoracic radiation, and the use of colony-stimulating factors or medication with pulmonary toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neutropenic enterocolitis: Topotecan-induced neutropenia may lead to typhlitis (neutropenic enterocolitis), including fatalities; should be considered in patients presenting with neutropenia, fever, and abdominal pain.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may require dose adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Topotecan exposure is increased when oral topotecan is used concurrently with P-glycoprotein inhibitors; avoid concurrent use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Safety issue: Topotecan overdoses have been reported; potential causes include omission of the leading zero and missing the decimal point when prescribing, preparing, and administering. Recommended intravenous doses should generally not exceed 4 mg in adults; verify dose prior to administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300156\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229264\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13005&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCRP/ABCG2 Inhibitors: May increase the serum concentration of Topotecan.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May decrease the serum concentration of Topotecan. Management: Monitor topotecan response closely, and consider alternatives to phenytoin when possible.  No specific guidelines for topotecan dose adjustment are available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Granulocyte Colony-Stimulating Factors: May enhance the myelosuppressive effect of Topotecan.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Topotecan.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Platinum Derivatives: May enhance the adverse/toxic effect of Topotecan.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: May increase the serum concentration of Topotecan.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229267\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229279\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. May cause fetal harm in pregnant women. Women of childbearing potential should use highly effective contraception to prevent pregnancy during treatment and for at least 1 month after therapy discontinuation. Males with female partners of childbearing potential should use highly effective contraception during treatment and for 3 months after therapy discontinuation. Topotecan may have both acute and long-term effects on fertility in women; fertility in males may be impaired due to effects on spermatogenesis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050401\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count; renal function tests; bilirubin; monitor for signs and symptoms of interstitial lung disease; diarrhea symptoms/hydration status </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229259\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to topoisomerase I and stabilizes the cleavable complex so that religation of the cleaved DNA strand cannot occur. This results in the accumulation of cleavable complexes and single-strand DNA breaks. Topotecan acts in S phase of the cell cycle. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229276\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Pharmacokinetic data in pediatric patients and young adults (0.4 to 22 years of age) demonstrated a high level of interpatient variability (43% to 57% dependent upon parameter evaluated) as well as intrapatient variability (20% to 22% dependent upon parameter evaluated) (Schaiquevich 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients and young adults (0.4 to 22 years of age): Mean range: 32.2 to 32.7 L/m<sup>2</sup> (Schaiquevich 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 25 to 75 L/m<sup>2</sup> (Hartmann 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~35%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Undergoes a rapid, pH-dependent hydrolysis of the lactone ring to yield a relatively inactive hydroxy acid in plasma; metabolized in the liver to N-demethylated metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: Capsule: Adults: ~40%; data from pediatric patients (1 to 18 years of age) showed that, while highly variable, the reported median oral bioavailability with oral administration of the reconstituted parenteral solution is similar to adults (Daw 2004; Zamboni 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (0 to 18 years of age): Lactone moiety: 2.58 hours &plusmn; 0.15 (range: 0.2 to 7.1 hours) (Santana 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: IV: 2 to 3 hours; renal impairment: ~5 hours; Oral: 3 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (1 to 18 years of age): Parenteral formulation (reconstituted lyophilized formulation): 0.75 to 2 hours (Zamboni 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Oral: 1 to 2 hours; delayed with high-fat meal (3 to 4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Urine (51%; ~3% as N-desmethyl topotecan); feces (18%; ~2% as N-desmethyl topotecan)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Urine (20%; 2% as N-desmethyl topotecan); feces (33%; &lt;2% as N-desmethyl topotecan)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (0.4 to 18 years of age): GFR most significant determinant of clearance; a linear model with GFR has been observed; BSA is also a significant determinant of clearance and AUC more so than patient weight; infants &lt;6 months have decreased clearance (Schaiquevich 2007). However, pharmacokinetic data from six pediatric patients with severe renal impairment (n=5: Unilateral nephrectomy; n=1: Anephric on hemodialysis) suggests that other mechanisms than GFR may assist with renal clearance; in these patients, overall systemic clearance was shown to be similar to matched controls (age, BSA, and Scr) despite decreased GFR (Iacono 2003; Iacono 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Topotecan plasma clearance is 24% higher in males than in female patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573965\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For patients unable to swallow capsules whole, reconstituted topotecan solution for injection (1 mg/mL concentration) may be mixed with up to 30 mL of acidic fruit juice (eg, apple, orange, grape) immediately prior to oral administration.</p>\n    <div class=\"reference\">Daw NC, Santana VM, Iacono LC, et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. <i>J Clin Oncol</i>. 2004;22(5):829-837.<span class=\"pubmed-id\">14990638</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324004\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Hycamtin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (10): $1,205.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (10): $4,823.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Topotecan HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/4 mL (4 mL): $128.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Hycamtin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (1): $1,389.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Topotecan HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (1): $282.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038846\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Camtoop (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Canol (LK);</li>\n      <li>Firotex (VN);</li>\n      <li>Hikamtyn (UA);</li>\n      <li>Hycamtin (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, MT, MY, NL, NO, NZ, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE, VN, ZW);</li>\n      <li>Oncotecan (CO, EC, PE);</li>\n      <li>Potactasol (IE, LV, MT);</li>\n      <li>Potekam (PY);</li>\n      <li>Topodria (CO);</li>\n      <li>Topokebir (AR);</li>\n      <li>Topotel (IN, PH, ZW);</li>\n      <li>Toranex (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ashraf K, Shaikh F, Gibson P, et al. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.<i> Pediatr Blood Cancer.</i> 2013;60(10):1636-1641.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/23650219/pubmed\" target=\"_blank\" id=\"23650219\">23650219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457&minus;a report from the Children's Oncology Group.<i> J Clin Oncol.</i> 2006;24(1):152-159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/16382125/pubmed\" target=\"_blank\" id=\"16382125\">16382125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bowers DC, Aquino VM, Leavey PJ, et al. Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors. <i>Pediatr Blood Cancer.</i> 2004;42(1):93-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/14752800/pubmed\" target=\"_blank\" id=\"14752800\">14752800</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Craig SB, Bhatt UH, and Patel K. Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers. <i>J Pharm Biomed Anal.</i> 1997;16(2):199-205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/9408834/pubmed\" target=\"_blank\" id=\"9408834\">9408834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daw NC, Santana VM, Iacono LC, et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. <i>J Clin Oncol.</i> 2004;22(5):829-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/14990638/pubmed\" target=\"_blank\" id=\"14990638\">14990638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. <i>J Clin Oncol.</i> 2007;25(15):2086-2092.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/17513814/pubmed\" target=\"_blank\" id=\"17513814\">17513814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furman WL, Stewart CF, Kirstein M, et al, &ldquo;Protracted Intermittent Schedule of Topotecan in Children With Refractory Acute Leukemia: A Pediatric Oncology Group Study,&rdquo; <i>J of Clin Oncology</i>, 2002, 20(6):1617-1624. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/11896112 /pubmed\" target=\"_blank\" id=\"11896112 \">11896112 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hartmann JT and Lipp HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.<i> Drug Saf.</i> 2006;29(3):209-230.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/16524321/pubmed\" target=\"_blank\" id=\"16524321\">16524321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hijiya N, Stewart CF, Zhou Y, et al. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. <i>Cancer. </i>2008;112(9):1983-1891.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/18318429/pubmed\" target=\"_blank\" id=\"18318429\">18318429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. <i>Pediatr Blood Cancer.</i> 2006;47(6):795-800.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/16411206/pubmed\" target=\"_blank\" id=\"16411206\">16411206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iacono LC, Adams D, Homans AC, et al. Topotecan disposition in an anephric child. <i>J Pediatr Hematol Oncol.</i> 2004;26(9):596-600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/15342988/pubmed\" target=\"_blank\" id=\"15342988\">15342988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iacono LC, Dome JS, Panetta JC, et al. Topotecan pharmacokinetics in children with Wilms tumor and unilateral nephrectomy. <i>Pharmacotherapy.</i> 2003;23:410.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inaba H, Stewart CF, Crews KR, et al. Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. <i>Cancer.</i> 2010;116(1):98-105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/19885837/pubmed\" target=\"_blank\" id=\"19885837\">19885837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kasow KA, Stewart CF, Barfield RC, et al. A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up. <i>Bone Marrow Transplant.</i> 2012;47(11):1448-1454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/22426752/pubmed\" target=\"_blank\" id=\"22426752\">22426752</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.<i> Cancer Treat Rev.</i> 1995;21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kretschmar CS, Kletzel M, Murray K, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.<i> J Clin Oncol.</i> 2004;22(20):4119-4126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/15483021/pubmed\" target=\"_blank\" id=\"15483021\">15483021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Cheung NK, Kramer K, et al. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.<i> Bone Marrow Transplant.</i> 2001;28(6):551-556.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/11607767/pubmed\" target=\"_blank\" id=\"11607767\">11607767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    London WB, Frantz CN, Campbell LA, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. <i>J Clin Oncol.</i> 2010;28(24):3808-3815.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/20660830/pubmed\" target=\"_blank\" id=\"20660830\">20660830</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minturn JE, Janss AJ, Fisher PG, et al, A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. <i>Pediatr Blood Cancer.</i> 2011;56(1):39-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/21108437/pubmed\" target=\"_blank\" id=\"21108437\">21108437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappo AS, Lyden E, Breneman J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. <i>J Clin Oncol</i>. 2001;19(1):213-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/11134215/pubmed\" target=\"_blank\" id=\"11134215\">11134215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.<i> J Clin Oncol</i>. 2011;29(33):4351-4357.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/22010014/pubmed\" target=\"_blank\" id=\"22010014\">22010014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubie H, Geoerger B, Frappaz D, et al. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. <i>Eur J Cancer</i>. 2010;46(15):2763-2770.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/20558056/pubmed\" target=\"_blank\" id=\"20558056\">20558056</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santana VM, Furman WL, Billups CA, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.<i> J Clin Oncol</i>. 2005;23(18):4039-4047.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/15961757/pubmed\" target=\"_blank\" id=\"15961757\">15961757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santana VM, Zamboni WC, Kirstein MN, et al, &ldquo;A Pilot Study of Protracted Topotecan Dosing Using a Pharmacokinetically Guided Dosing Approach in Children With Solid Tumors,&rdquo; <i>Clin Cancer Res</i>, 2003, 9(2):633-640. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/12576429/pubmed\" target=\"_blank\" id=\"12576429\">12576429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saylors RL 3rd, Stine KC, Sullivan J, et al, &ldquo;Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study,&rdquo; <i>J Clin Oncol</i>, 2001, 19(15):3463-3469. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/11481351/pubmed\" target=\"_blank\" id=\"11481351\">11481351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaiquevich P, Panetta JC, Iacono LC, et al. Population pharmacokinetic analysis of topotecan in pediatric cancer patients. <i>Clin Cancer Res</i>. 2007;13(22 Pt 1):6703-6711.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/18006771/pubmed\" target=\"_blank\" id=\"18006771\">18006771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sehouli J, Stengel D, Harter P, et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. <i>J Clin Oncol</i>. 2011;29(2):242-248.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/21115872/pubmed\" target=\"_blank\" id=\"21115872\">21115872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner S, Erdlenbruch B, L&auml;ngler A, et al. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. <i>Cancer</i>. 2004;100(8):1750-1757.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/15073866/pubmed\" target=\"_blank\" id=\"15073866\">15073866</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walterhouse DO, Lyden ER, Breitfeld PP, et al, &ldquo;Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children With Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children's Oncology Group Study,&rdquo; <i>J Clin Oncol</i>, 2004, 22(8):1398-1403. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/15007087/pubmed\" target=\"_blank\" id=\"15007087\">15007087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wells RJ, Reid JM, Ames MM, et al, &ldquo;Phase I Trial of Cisplatin and Topotecan in Children With Recurrent Solid Tumors: Children's Cancer Group Study 0942,&rdquo; <i>J Pediatr Hematol Oncol</i>, 2002, 24(2):89-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/11990712/pubmed\" target=\"_blank\" id=\"11990712\">11990712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zage PE, Kletzel M, Murray K, et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. <i>Pediatr Blood Cancer</i>. 2008;51(6):747-753.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/18704922/pubmed\" target=\"_blank\" id=\"18704922\">18704922</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zamboni WC, Bowman LC, Tan M, et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. <i>Cancer Chemother Pharmacol</i>. 1999;43(6):454-460.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topotecan-pediatric-drug-information/abstract-text/10321504/pubmed\" target=\"_blank\" id=\"10321504\">10321504</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13005 Version 154.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708912\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F229294\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F229295\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050402\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050394\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F229271\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F229256\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050405\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132737\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F229286\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050404\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F229339\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F229336\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F229277\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F229260\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300156\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F229264\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F229267\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F229279\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050401\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F229259\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F229276\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F25573965\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324004\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038846\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13005|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=topotecan-drug-information\" class=\"drug drug_general\">Topotecan: Drug information</a></li><li><a href=\"topic.htm?path=topotecan-patient-drug-information\" class=\"drug drug_patient\">Topotecan: Patient drug information</a></li></ul></div></div>","javascript":null}